Literature DB >> 9601160

Efficacy of analgesics in chronic pain: a series of N-of-1 studies.

R B Sheather-Reid1, M Cohen.   

Abstract

Rational drug treatment of chronic musculoskeletal pain remains a challenge. Although commonly prescribed, the true efficacy of opioid analgesics or of nonsteroidal antiinflammatory drugs remains to be established. Using an N-of 1 design, eight patients with regional cervicobrachial pain received ibuprofen 800 mg/day, codeine 120 mg/day, or placebo during six 2 week periods. Clinical outcomes were assessed by pain diary, VAS of pain and change in pain, and uptime/downtime estimates. In none of the five subjects who completed the 12-week trial was analgesic efficacy of either drug shown. Major psychosocial and other medical influences on the subjects' status were encountered. The N-of 1 methodology is appropriated for evaluating true efficacy of pharmacotherapy in patients with regional musculoskeletal pain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9601160     DOI: 10.1016/s0885-3924(98)00369-8

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  10 in total

Review 1.  [Chronic pain in everyday medical routine].

Authors:  D Rothstein; M Zenz
Journal:  Internist (Berl)       Date:  2005-10       Impact factor: 0.743

2.  Using N-of-1 trials to improve patient management and save costs.

Authors:  Paul A Scuffham; Jane Nikles; Geoffrey K Mitchell; Michael J Yelland; Norma Vine; Christopher J Poulos; Peter I Pillans; Guy Bashford; Chris del Mar; Philip J Schluter; Paul Glasziou
Journal:  J Gen Intern Med       Date:  2010-04-13       Impact factor: 5.128

Review 3.  A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain.

Authors:  Andrea Furlan; Luis E Chaparro; Emma Irvin; Angela Mailis-Gagnon
Journal:  Pain Res Manag       Date:  2011 Sep-Oct       Impact factor: 3.037

4.  Using n-of-1 trials as a clinical tool to improve prescribing.

Authors:  C Jane Nikles; Alexandra M Clavarino; Chris B Del Mar
Journal:  Br J Gen Pract       Date:  2005-03       Impact factor: 5.386

5.  Influence of ibuprofen addition on the properties of a bioactive bone cement.

Authors:  P P Lopes; M S Silva; M H V Fernandes
Journal:  J Mater Sci Mater Med       Date:  2013-05-16       Impact factor: 3.896

6.  The promotion and marketing of oxycontin: commercial triumph, public health tragedy.

Authors:  Art Van Zee
Journal:  Am J Public Health       Date:  2008-09-17       Impact factor: 9.308

7.  Epidemiology of regular prescribed opioid use: results from a national, population-based survey.

Authors:  Teresa J Hudson; Mark J Edlund; Diane E Steffick; Shanti P Tripathi; Mark D Sullivan
Journal:  J Pain Symptom Manage       Date:  2008-07-10       Impact factor: 3.612

8.  The PREEMPT study - evaluating smartphone-assisted n-of-1 trials in patients with chronic pain: study protocol for a randomized controlled trial.

Authors:  Colin Barr; Maria Marois; Ida Sim; Christopher H Schmid; Barth Wilsey; Deborah Ward; Naihua Duan; Ron D Hays; Joshua Selsky; Joseph Servadio; Marc Schwartz; Clyde Dsouza; Navjot Dhammi; Zachary Holt; Victor Baquero; Scott MacDonald; Anthony Jerant; Ron Sprinkle; Richard L Kravitz
Journal:  Trials       Date:  2015-02-27       Impact factor: 2.279

9.  Is pharmacologic treatment better than neural mobilization for cervicobrachial pain? A randomized clinical trial.

Authors:  César Calvo-Lobo; Francisco Unda-Solano; Daniel López-López; Irene Sanz-Corbalán; Carlos Romero-Morales; Patricia Palomo-López; Jesús Seco-Calvo; David Rodríguez-Sanz
Journal:  Int J Med Sci       Date:  2018-03-08       Impact factor: 3.738

10.  Effectiveness of median nerve neural mobilization versus oral ibuprofen treatment in subjects who suffer from cervicobrachial pain: a randomized clinical trial.

Authors:  David Rodriguez Sanz; Francisco Unda Solano; Daniel López López; Irene Sanz Corbalan; Carlos Romero Morales; Cesar Calvo Lobo
Journal:  Arch Med Sci       Date:  2017-09-26       Impact factor: 3.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.